About: Application of siRNA Against SARS in the Rhesus Macaque Model

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Application of siRNA Against SARS in the Rhesus Macaque Model Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Application of siRNA Against SARS in the Rhesus Macaque Model
Creator	Lu, Patrick Woodle, Martin Tang, Qingquan Li, Baojian
topic	covid:e78f5fd17168e653f6399e064ed969e52ed612ff#this
Source	Medline; PMC
abstract	Containment of the SARS coronavirus (SCV) outbreak was accompanied by the rapid characterization of this new pathogen's genome sequence in 2003, encouraging the development of anti-SCV therapeutics using short interfering RNA (siRNA) inhibitors. A pair of siRNA duplexes identified as potent SCV inhibitors in vitro was evaluated for in vivo efficacy and safety in a rhesus macaque SARS model using intranasal administration with clinical viable delivery carrier in three dosing regimens. Observations of SCV-induced SARS-like symptoms, measurements of SCV RNA presence in the respiratory tract, microscopic inspections of lung histopathology, and immunohistochemistry sections from 21 tested macaques consistently demonstrated siRNA-mediated anti-SCV activity. The prophylactic and therapeutic efficacies resulted in relief of animals from SCV infection-induced fever, diminished SCV in upper airway and lung alveoli, and milder acute diffuse alveoli damage (DAD). The dosages of siRNA used, 10 to 40 mg/kg, did not show any sign of siRNA-induced toxicity. These results support that a clinical investigation of this anti-SARS siRNA therapeutic agent is warranted. The study also illustrates the capability of siRNA to enable a massive reduction in development time for novel targeted therapeutic agents. We detail a representative example of large-mammal siRNA use.
has issue date	2008-01-01(xsd:dateTime)
bibo:doi	10.1007/978-1-59745-191-8_11
bibo:pmid	18369784
has license	no-cc
sha1sum (hex)	e78f5fd17168e653f6399e064ed969e52ed612ff
schema:url	https://doi.org/10.1007/978-1-59745-191-8_11
resource representing a document's title	Application of siRNA Against SARS in the Rhesus Macaque Model
has PubMed Central identifier	PMC7121115
has PubMed identifier	18369784
schema:publication	RNAi
resource representing a document's body	covid:e78f5fd17168e653f6399e064ed969e52ed612ff#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/e78f5fd17168e653f6399e064ed969e52ed612ff
is schema:about of	named entity 'sections' named entity 'duplexes' named entity 'lung' named entity 'study' named entity 'accompanied' named entity 'SCV' named entity 'time' named entity 'genome' named entity 'CARRIER' named entity 'STUDY' named entity 'EXAMPLE' named entity 'ALVEOLI' named entity 'REPRESENTATIVE' named entity 'SYMPTOMS' named entity 'SIGN OF' named entity 'RELIEF' named entity 'SHORT INTERFERING RNA' named entity 'INTRANASAL ADMINISTRATION' named entity 'PROPHYLACTIC' named entity 'PATHOGEN' named entity 'CLINICAL' named entity 'FEVER' named entity 'MASSIVE' named entity 'MODEL' named entity 'DID' named entity 'DIMINISHED' named entity 'REGIMENS' named entity 'RHESUS MACAQUE' named entity 'TARGETED' named entity 'RNA' named entity 'SARS' named entity 'MAMMAL' named entity 'EVALUATED' named entity 'THERAPEUTIC AGENT' named entity 'THERAPEUTICS' named entity 'MACAQUES' named entity 'SARS CORONAVIRUS' named entity 'TOXICITY' named entity 'MODEL' named entity 'SIRNA' named entity 'APPLICATION' named entity 'SARS' named entity 'NEW' named entity 'USING' named entity 'DEVELOPMENT' named entity 'LIKE' named entity 'NOVEL' named entity 'GENOME SEQUENCE' named entity 'INSPECTIONS' named entity 'OUTBREAK' named entity 'CLINICAL INVESTIGATION' named entity 'SCV' named entity 'PAIR' named entity 'REDUCTION' named entity 'MEASUREMENTS' named entity 'PRESENCE' named entity 'LUNG' named entity 'RESPIRATORY TRACT' named entity 'LARGE' named entity 'THESE' named entity 'ANIMALS' named entity 'THERAPEUTIC' named entity 'RHESUS MACAQUE' named entity 'CONTAINMENT' named entity 'CHARACTERIZATION' named entity 'TIME' named entity 'MEDIATED' named entity 'VIABLE' named entity 'INDUCED' named entity 'RAPID' named entity 'CAPABILITY' named entity 'ACUTE DIFFUSE' named entity 'USED' named entity 'IN VITRO' named entity 'TESTED' named entity 'MG%'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software